Drug Type Radiolabeled antibody, Diagnostic radiopharmaceuticals |
Synonyms Radionuclide olaratumab conjugate - Telix Pharmaceuticals |
Target |
Action inhibitors |
Mechanism PDGFRα inhibitors(Platelet-derived growth factor receptor alpha inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Sarcoma | Discovery | Australia | 01 Apr 2022 |